Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 11/20 | 0.65 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | IL1B | P01584 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8410540 | 0.94 | CASP1 (0.59) | CASP1CAPN1CASP3L3MBTL1ACE | |
| SCHEMBL5682688 | 0.89 | CASP1 (0.64) | CASP1CAPN1CASP3ACE | |
| SCHEMBL5682945 | 0.79 | CASP1 (0.63) | CASP1CAPN1 | |
| SCHEMBL5680708 | 0.79 | CASP1 (0.75) | CASP1CASP3L3MBTL1 | |
| SCHEMBL5683299 | 0.78 | CASP1 (0.82) | CASP1 | |
| SCHEMBL5680762 | 0.78 | CASP1 (0.66) | CASP1CASP3L3MBTL1 | |
| SCHEMBL5682786 | 0.77 | CASP1 (0.73) | CASP1 | |
| SCHEMBL5682911 | 0.77 | CASP1 (0.68) | CASP1 | |
| SCHEMBL5680759 | 0.77 | CASP1 (0.65) | CASP1CASP3L3MBTL1 | |
| SCHEMBL5681240 | 0.77 | CASP1 (1.00) | CASP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0932600-B1 | SULFONAMIDE SUBSTITUTED ASPARTIC ACID INTERLEUKIN-1BETA CONVERTING ENZYME INHIBITORS | WARNER LAMBERT CO (US) | 2006-02-08 | — | — | EP | claimed |
| US-6083981-A | USEFUL FOR TREATMENT OF STROKE, INFLAMMATORY DISEASES, SEPTIC SHOCK, REPERFUSION INJURY, ALZHEIMER'S DISEASE, SHIGELLOSIS | WARNER-LAMBERT COMPANY (US) | 2000-07-04 | — | — | US | claimed |
| EP-0932600-A2 | SULFONAMIDE SUBSTITUTED ASPARTIC ACID INTERLEUKIN-1$g(b) CONVERTING ENZYME INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-08-04 | — | — | EP | claimed |
| WO-1998016504-A2 | SULFONAMIDE SUBSTITUTED ASPARTIC ACID INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1998-04-23 | — | — | WO | claimed |
| EP-0932600-B1 | SULFONAMIDE SUBSTITUTED ASPARTIC ACID INTERLEUKIN-1BETA CONVERTING ENZYME INHIBITORS | WARNER LAMBERT CO (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2001019373-A2 | METHODS AND COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| US-6083981-A | USEFUL FOR TREATMENT OF STROKE, INFLAMMATORY DISEASES, SEPTIC SHOCK, REPERFUSION INJURY, ALZHEIMER'S DISEASE, SHIGELLOSIS | WARNER-LAMBERT COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0998300-A1 | METHODS AND COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-10 | — | — | EP | disclosed |
| US-6054487-A | ADMINISTERING AN INTERLEUKIN-ONE BETA CONVERTING ENZYME SUFFICIENT TO INHIBIT PRODUCTION OF GAMMA-INTERFERON | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-25 | — | — | US | disclosed |
| EP-0932600-A2 | SULFONAMIDE SUBSTITUTED ASPARTIC ACID INTERLEUKIN-1$g(b) CONVERTING ENZYME INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-08-04 | — | — | EP | disclosed |
| WO-1998041232-A2 | COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | disclosed |
| WO-1998016504-A2 | SULFONAMIDE SUBSTITUTED ASPARTIC ACID INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |